Evidence map›Paper›PMID 41945868›Full record

Observational studyJMIR public health and surveillance2026

Barriers and Opportunities to Include Underrepresented Population Groups in Vaccine Trials: Cross-Sectional, Observational, Online Survey Study From the VACCELERATE Research Network.

Mine Durusu Tanriover, Dimitrios Poulimeneas, Grammatiki-Christina Tsopela, Ioannis Kopsidas, Christos Argyropoulos, Romina Di Marzo, Olena Valdenmaiier, Stine Finne Jakobsen, Paula Valle Simon, Antonio Javier Carcas-Sansuan and 5 more

Abstract readObservational Study
In one paragraph

Observational study in JMIR public health and surveillance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mine Durusu TanrioverDepartment of Internal Medicine, Faculty of Medicine, Hacettepe Üniversitesi Aşı Enstitüsü Sıhhiye, Ankara, 06230, Turkey, 90 312 305 3069.ORCID 0000-0001-9565-4389
Dimitrios PoulimeneasCollaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece.ORCID 0000-0003-4868-9620
Grammatiki-Christina TsopelaCollaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece.ORCID 0000-0003-3662-0140
Ioannis KopsidasCollaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece.ORCID 0000-0001-6499-4807
Christos ArgyropoulosChemical Engineering Department, King Fahd University of Petroleum & Minerals (KFUPM), Dhahran, Saudi Arabia.ORCID 0000-0002-2090-2162
Romina Di MarzoEuropean Vaccine Initiative (EVI), Heidelberg, Germany.ORCID 0000-0002-8715-0348
Olena ValdenmaiierCentre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-7882-2635
Stine Finne JakobsenCentre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-2586-0248
Paula Valle SimonHospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.ORCID 0000-0002-3399-9725
Antonio Javier Carcas-SansuanHospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.ORCID 0000-0003-1823-4174
Ole F OlesenEuropean Vaccine Initiative (EVI), Heidelberg, Germany.ORCID 0000-0002-3025-2466
Oliver A CornelyCologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Institute of Translational Research, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0001-9599-3137
Zoi Dorothea PanaSchool of Medicine, Department of Basic & Clinical Sciences, University of Nicosia, Nicosia, Cyprus.ORCID 0000-0002-5893-1081
Theoklis ZaoutisCollaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece.ORCID 0000-0003-0127-6562
Murat AkovaVaccine Institute, Hacettepe University, Ankara, Turkey.ORCID 0000-0002-6904-9473

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite the vast growth of vaccine studies during the SARS-CoV-2 pandemic, clinical trials failed to adequately represent diverse societal groups, resulting in the underrepresentation of specific populations. Understanding the factors hampering participation in vaccine clinical trials is essential to better identify structural, ethical, and communication barriers and to improve inclusive strategies for broader and more equitable participation in future vaccine research. Objective: This study aimed to identify the perceived barriers to participation in vaccine trials among pregnant and lactating women, children aged younger than 18 years, and adults aged older than 65 years, as reported by professionals with expertise in vaccines or vaccine trials. Methods: An online questionnaire was developed to gather personal information, group-specific barriers to vaccine trial participation, and suggestions to overcome these barriers. Data are presented as absolute (n/N) and relative frequencies (%). Results: A total of 115 respondents, the majority (n=73, 63.5%) of whom were working in the scientific community, completed the online survey. Challenges in recruiting children were identified due to "safety or efficacy concerns," "difficulties about ethics and regulatory issues," and "lack of targeted information and communication." Challenges in recruiting pregnant and lactating women were primarily "ethics and regulatory requirements," "safety issues," and "lack of prioritization or interest." "Lack of information and communication channels adapted to the specific target group," along with "lack of prioritization," were the main challenges in recruiting older participants. Provision of health-related incentives, including but not limited to access to new treatments and receiving expert medical care, seems to be the top-rated motivation to participate in vaccine clinical trials. Conclusions: The main challenges in recruiting pregnant and lactating women and children in vaccine trials involve safety and efficacy concerns, as well as lengthy ethical and regulatory processes. For older adults, key issues include poor communication channels tailored to their needs, limited information, lack of prioritization, funding, infrastructure, and industry interest. Across all underrepresented groups, low awareness of and poor communication about research opportunities were major barriers. Additionally, mobility issues affected older adults, while lack of motivation and incentives affected children, and low health literacy and provider uncertainty impacted pregnant and lactating women. Improving communication infrastructure and enhancing communication strategies with clear, tailored messages to build trust and motivate participation are essential to improve inclusion in vaccine research.

Indexed as

Clinical Trials as TopicPatient SelectionAdolescentAdultAgedChildCOVID-19COVID-19 VaccinesCross-Sectional StudiesFemaleHumansMaleMiddle AgedPregnancySurveys and QuestionnairesCOVID-19 VaccinesbarriersCOVID-19pandemic preparednessvaccinationsvaccine trialsvolunteer registry

Identifiers

PMID41945868
PMCPMC13056233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.